Skip to main content
Resources

News

Stay current with our recent news, updates, and announcements.
Casey Frushour
In News

Infinity Bio Wins Gold at the 2024 MarCom Awards for Website Excellence

MarCom Gold Winner
Infinity Bio is proud to announce that we’ve been awarded a prestigious Gold MarCom Award for our website. This recognition highlights our commitment to not only advancing scientific innovation but also ensuring that our digital presence reflects the cutting-edge work we do in antibody profiling. Our newly designed website was crafted to enhance the user experience, making it easier for our visitors to explore our mission and innovations. We’re honored to be recognized by MarCom for excellence in web design and communication.
Read More
Casey Frushour
In Press Releases

Infinity Bio Hosts Community Event for Baltimore’s Brightest Students

Infinity Bio, Inc., a biotechnology company specializing in antibody reactome profiling, hosted a special community event aimed at engaging and inspiring Baltimore children with an interest in STEM. The event took place on July 22, 2024, at Infinity Bio’s office and laboratory at 6200 Seaforth Street, Baltimore, MD, and featured various activities designed to spark interest in science and technology.
Read More
Casey Frushour
In Press Releases

Infinity Bio To Host Open House at State-of-the-Art Laboratory

Infinity Bio, a technology company known for its innovative antibody reactome profiling service, will host an open house event at its state-of-the-art laboratory at 6200 Seaforth Street in Baltimore on July 23, 2024. This event is designed to give members of the local scientific and biotech community an exclusive look at the research and technologies that are driving developments in immunology.
Read More
Casey Frushour
In News

Infinity Bio Launches Next-Generation Antibody Profiling Platform Utilizing MIPSA Technology

Infinity Bio, Inc. announces its new antibody profiling platform, leveraging Molecular Indexing of Proteins by Self-Assembly (MIPSA) technology. This platform offers unparalleled depth in immune system analysis, advancing immunology, virology, autoimmunity, and allergy research, providing new disease insights, and discovering new biomarkers and treatments. The MIPSA technology exploits recent advances in high throughput DNA sequencing and DNA synthesis, to create and analyze the most complete panels of immune targets available.
Read More